Thyquidity (Levothyroxine Sodium) Patent Expiration, LOE Window & CMS Spending

Thyquidity (Levothyroxine Sodium) by Jerome Stevens: FDA Orange Book LOE 2031-08-06, 7 AB generics, $614K 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJerome Stevens
FDA Application & PathwayN214047 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-08-06
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors7
2024 CMS Total Public Spend$614K
2024 Medicare Part D Spend$257K
2024 Medicaid Spend$357K
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 19.9% 2-yr change)